Do you agree to cookies? We use cookies on our website to offer you the best experience and to personalize the content you see. We also report analytics about our visitors on this website and other media. To find out more see our Terms of Use and Privacy Policy.

Skip to content
Important Safety Information Back to Glaukos.com

Connect with a doctor who performs the only FDA-approved cross-linking procedure and can discuss referrals for imaging.

Find a doctor Find an iLink® Provider

Resources

Check out these resources and become an iDetective to help slow or halt the progression of keratoconus!
All Case Studies Diagnostic Aids KC Clues

KC File #4: A Troublesome Toric Contact Lens Fit

 Read More

KC File #3: KC Masquerading as Myopia

 Read More

KC File #2: Autorefractor Clues That Were Ignored

 Read More

KC File #1: The Patient Who Corrects to 20/20

 Read More

Auto-Refractor Card

 Order Card

Topographer Card

 Order Card

Eye Rubbing & Ocular Allergy

 View PDF

Topographic Irregularities

 View PDF

Increasing and/or Unusual Astigmatism

 View PDF

Retinoscopy and Ophthalmoscopy Signals

 View PDF

Contact Lens Considerations

 View PDF

Visual Quality Complaints

 View PDF

Down Syndrome

 View PDF

Unusual Keratometry (K)

 View PDF

Abnormal Slit Lamp Examination

 View PDF

Genetics

 View PDF

Connective Tissue Disorders

 View PDF

Unusual Auto-refractor Reading

 View PDF

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.*1

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, click View Prescribing Information button below to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022.

View Prescribing Information